Summary
The effect of a sustained-release verapamil preparation on glucose metabolism was investigated in 10 patients with non-insulin dependent diabetes mellitus.
In a single blind cross-over study verapamil 240 mg b.d. for 1 week lowered fasting plasma glucose from a mean value of 11.6 mmol/l to 10.3 mmol·l−1, and the fasting glucose appearance rate was decreased from 1.5 to 1.2 mmol·min−1. The decrease in fasting plasma glucose and glucose appearance rate was not related to the steady state plasma concentration of verapamil, nor-verapamil and the metabolites D.617 and D.620.
After oral glucose administration a tendency to lower plasma glucose values was found after verapamil administration. Plasma insulin, C-peptide, total and C-terminal glucagon were not significantly different in the placebo and the verapamil studies, neither in the fasting state nor after glucose.
It is concluded that brief verapamil treatment decreases fasting plasma glucose and glucose turn-over in non-insulin dependent diabetics, possibly by inhibition of gluconeogenesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Trost BN, Weidman P (1984) Effects of nitrendipine and other calcium antagonists on glucose metabolism in man. J Cardiovasc Pharmacol 6: S986-S995
Millar JA, Struthers AD (1984) Calcium antagonists and hormone release. Clin Sci 66: 249–255
McTavish D, Sorkin EM (1989) Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38: 19–76
Semple CG, Thomson JA, Beastall GH, Lorimer AR (1983) Oral verapamil does not affects glucose tolerance in non-diabetics. Br J Clin Pharmacol 15: 570–571
Røjdmark S, Andersson DEH (1988) Influence of verapamil on human glucose tolerance. Am J Cardiol 57: 39D-43D
Gasic S, Bratusch-Marain P, Waldhausl W, Korn A (1988) Effect of verapamil on basal and glucagon-dependent splanchnic glucose metabolism and insulin secretion in man. Int J Clin Pharmacol Ther Tox 26: 36–40
Whitcroft I (1985) Do antihypertensive drugs precipitate diabetes? Br Med J 290: 322
Cruickshank JK, Anderson N, McFinitials, Wadsworth J, McHardy Young S, Jepson E (1988) Treating hypertension in black compared with white non-insulin dependent diabetics: A double blind trial of verapamil and metoprolol. Br Med J 297: 1155–1159
Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J (1989) The effects of verapamil, diltiazem, nifedipine and propranolol in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertension 3: 35–39
Andersson DEH, Røjdmark S (1981) Improvement in glucose tolerance by verapamil in patients with non-insulin dependent diabetes mellitus. Acta Med Scand 210: 27–33
Trinder P (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann Clin Biochem 6: 24–27
Lauridsen UB, Christensen NJ, Lyngsøe J (1983) Effects of non-selective and beta-1-selective blockade on glucose metabolism and hormone responses in normal man. J Clin Endocrinol Metab 56: 876–882
Heding LG (1972) Determination of total serum insulin (IRI) in insulin treated diabetic patients. Diabetologia 8: 260–266
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (Residues 33–69) of glicentin. Biochem J 207: 381–388
Mølgaard H, Bjerregaard P, Jørgensen HS, Klitgaard NA (1987) 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. Eur J Clin Pharmacol 33: 447–453
Røjdmark S, Andersson DEH (1984) Influence of verapamil on glucose tolerance. Acta Med Scand 34 [Suppl 681]: 37–42
Devis G, Somers G, Van Obberghen E, Malaisse WJ (1975) Calcium antagonists and islet function. I. Inhibition of insulin release by verapamil. Diabetes 24: 547–551
Hermansen K, Iversen J (1977) Effect of verapamil on pancreatic glucagon release freom the isolated perfused canine pancreas. Scand J Clin Lab Invest 37: 139–142
Shamoon H, Baylor P, Kambosis D, Charlap S, Plawes S, Frishman WH (1985) Influence of oral verapamil on glucoregulatory hormones in man. J Clin Endocrinol Metab 60: 536–541
Semple CG, Omile C, Buchanan KD, Beastall GH, Paterson KR (1986) Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 22: 187–190
Barbarino A, De Marinis L, Mancini A, Calabro F, Massarri M (1988) Calcium antagonists and hormone release VI: Effects of a calcium abtagonist (Verapamil) on the biphasic insulin release in vivo. Diabetes Res 8: 21–24
Andersson DEH (1984) Effect of verapamil on insulin release and glucose metabolism in man. Thesis, Stockholm p35
Jespersen CM, Klitgaard NA, Nielsen H, Fischer Hansen J (1989) Sustained-release and instant-release verapamil in treatment of angina pectoris. Eur J Clin Pharmacol 36: 625–627
Zachariah PK, Shub C, Sheps SG, Schirger A, Wolf MK, Carlson CA (1988) Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. J Clin Pharmacol 28: 843–847
Geigy Wissenschaftliche Tabellen. Geigy, Basel (196), pp 181–182
Author information
Authors and Affiliations
Additional information
The work was supported by a grant from Knoll AG, FRG, who also supplied the sustained release verapamil and placebo tablets
Rights and permissions
About this article
Cite this article
Sørensen, M.B., Sjøstrand, H., Sengeløv, H. et al. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 41, 401–404 (1991). https://doi.org/10.1007/BF00626359
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00626359